SANOFI SA INHABER EO 2/ FR0000120578 /
27/12/2024 21:31:12 | Chg. +0.560 | Volume | Bid21:59:59 | Demandez à21:59:59 | Capitalisation boursière | Dividende Y. | Rapport P/E |
---|---|---|---|---|---|---|---|
93.420EUR | +0.60% | 4,774 Chiffrre d'affaires: 441,275.960 |
93.190Bid taille: 110 | 93.380Ask la taille: 110 | 116.94 Mrd.EUR | 4.03% | 21.64 |
GlobeNewswire
02/09
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
26/08
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
14/08
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
13/08
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
12/08
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
08/08
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
07/08
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
06/08
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
01/08
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
31/07
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
25/07
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
25/07
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page